OPRM1 and CYP2B6 Gene Variants as Risk Factors in Methadone‐Related Deaths

@article{Bunten2010OPRM1AC,
  title={OPRM1 and CYP2B6 Gene Variants as Risk Factors in Methadone‐Related Deaths},
  author={Hannah Bunten and Wei Liang and Derrick J. Pounder and Collin Seneviratne and David Osselton},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2010},
  volume={88}
}
Methadone is a medication valued for its effectiveness in the treatment of heroin addiction; however, many fatal poisonings associated with its use have been reported over the years. We have examined the association between CYP2B6 and µ‐opioid receptor (OPRM1) gene variations and apparent susceptibility to methadone poisoning. Genomic DNA was extracted from postmortem whole blood of 40 individuals whose deaths were attributed to methadone poisoning. The presence of CYP2B6*4,*9, and *6 alleles… 

Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations.

TLDR
The prevalence of CYP2B6 and μ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays.

CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction

TLDR
The mean methadone doses required by subjects homozygous for the variant alleles of the CYP2B6 SNPs 785A>G and 516G>T were significantly lower than those of the heterozygotes and the non‐carriers and the results remain significant after controlling for age, sex and the ABCB1 SNP 1236C>T.

Haplotype-Based Association and In Silico Studies of OPRM1 Gene Variants with Susceptibility to Opioid Dependence Among Addicted Iranians Undergoing Methadone Treatment

TLDR
Results revealed that rs495491, A118G, rs589046, and rs10457090 variants of OPRM1 gene with opium dependence and their haplotypes among addicted individuals undergoing methadone treatment were associated with opioid dependence among Iranians; also, A 118G might be the most remarkable marker of O PRM1 owing to its vital structural roles.

Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients.

TLDR
Findings provide new insight to the fact that the interindividual variability of methadone dosage requirement is polygenetic and cannot be explained by a single-gene effect.

CYP2B6, ABCB1 and OPRM1 profile in a stillborn affected by chronic methadone intoxication

TLDR
Because of the safety of fetal MTD exposure, the stillborn case reported by the group must be considered an exceptional event given that MTD has been recommended for treating heroin addiction during pregnancy since the early 1970s, and is considered extremely safe at therapeutic dosages.

Pharmacogenomics of methadone: a narrative review of literature.

TLDR
Evidence remains scarce at this time, to recommend pharmacogenetic testing before methadone administration, and well-powered clinical studies are needed with population pharmacokinetic-pharmacodynamic modeling and multigenetic signature-based predictions to enable tailored use of methamphetamineadone in clinical practice.

Genetic Polymorphism and Toxicology — With Emphasis on Cytochrome P 450

TLDR
An update of the field with emphasis on CYP polymorphism is provided, where an increasing number of pharmacogenomic drug labels are assigned, where the predictive genotyping before drug treatment can be mandatory, recommended, or only for informational purposes.

Genetic polymorphism and toxicology--with emphasis on cytochrome p450.

TLDR
An update of the field with emphasis on CYP polymorphism is provided, where an increasing number of pharmacogenomic drug labels are assigned, where the predictive genotyping before drug treatment can be mandatory, recommended, or only for informational purposes.

Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study

TLDR
Known genetic polymorphisms in CYP2B6 contribute toward explaining extreme (S)-methadone plasma levels observed in a cohort of patients following methadone maintenance treatment.
...

References

SHOWING 1-10 OF 60 REFERENCES

Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity?

TLDR
It is hypothesized that methadone toxicity may be partially due to CYP 2D6 *3, *4, and *5 variant alleles, resulting in poor drug metabolism, and pharmacogenomics, complementing other case findings, served as an adjunct in interpreting methdone toxicity of poor and intermediate metabolizers.

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

TLDR
Only a minor fraction of the variability in bupropion and hydroxybupropion kinetics could be explained by the known CYP2B6 amino acid variants, in particular by the CYP1B6*4 allele.

Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G*

TLDR
Results indicate that OPRM1-G118 is a functional variant with deleterious effects on both mRNA and protein yield, and clarifying the functional relevance of polymorphisms associated with susceptibility to a complex disorder such as drug addiction provides a foundation for clinical association studies.

Does the A118G Polymorphism at the &mgr;-opioid Receptor Gene Protect against Morphine-6-Glucuronide Toxicity?

TLDR
The authors hypothesize that the A118G single nucleotide polymorphism of the &mgr;-opioid-receptor is among the protective factors against M6G-related opioid toxicity.

Methadone Toxicity Fatalities: A Review of Medical Examiner Cases in a Large Metropolitan Area *

TLDR
This study reviews 176 fatalities ascribed to methadone toxicity by the Office of the Chief Medical Examiner in Kentucky between 2000 and 2004 and finds that a thorough investigation into the practices of procurement and use/abuse of methamphetamineadone is essential to arrive at the proper designation of the cause of death.

Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6

TLDR
Inhibitors of CYP2B6 were identified from a wide variety of therapeutic classes and clopidogrel and ticlopidine were identified as being of concern as potential inhibitors of clinical relevance.

The pharmacokinetics of methadone in healthy subjects and opiate users.

TLDR
Estimates of the long terminal elimination half-life of methadone indicated that accurate measurement of this parameter requires a duration of sampling longer than that used in this study, and parameters describing plasma concentrations of methamphetamine after a single oral dose in healthy subjects may not be used for predicting and adjusting dosage in opiate users receiving methamphetamineadone maintenance therapy unless coupled with feedback concentration monitoring techniques.

Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.

TLDR
Single nucleotide polymorphisms in CYP3A4 were identified by direct sequencing of genomic DNA in 72 individuals from three different ethnic groups, including Caucasians, Blacks (African-Americans and African pygmies), and Asians, and racial variability was observed for the frequency of individual SNPs.

μ opioid receptor gene variants: lack of association with alcohol dependence

TLDR
Data do not support a role of the μ opioid receptor in susceptibility to alcohol dependence, but the potential relationship between OPRM1 genetic variation and response to endogenous opioids and exogenous opiates can now be investigated.

Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

  • C. BondK. Laforge L. Yu
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1998
TLDR
Results show that SNPs in the mu opioid receptor gene can alter binding and signal transduction in the resulting receptor and may have implications for normal physiology, therapeutics, and vulnerability to develop or protection from diverse diseases including the addictive diseases.
...